ABSTRACT
Objective To determine whether height has a causal effect on risk of atrial fibrillation
Design Mendelian randomization study
Setting Genome-wide association studies of height and atrial fibrillation; Penn Medicine Biobank
Participants Multiethnic (predominantly European ancestry) participants in genome-wide association studies of height (693,529 individuals) and atrial fibrillation (65,446 cases and 522,744 controls); 7,023 Penn Medicine Biobank participants of European ancestry
Exposures Height, cardiometabolic risk factors for atrial fibrillation, and randomly allocated genetic variants strongly associated with these traits
Main outcome measure Risk of atrial fibrillation (measured in odds ratio)
Results At the population level, a 1 standard deviation increase in genetically-predicted height was associated with increased odds of AF (Odds ratio [OR] 1.34; 95% Confidence Interval [CI] 1.29 to 1.40; p = 5×10−42). These findings remained consistent in sensitivity analyses that were robust to the presence of pleiotropic variants. Results from analyses considering individual-participant data were similar, even after adjustment for clinical covariates, including left atrial size.
Conclusion Genetically predicted height is a positive causal risk factor for AF. This finding raises the possibility of investigating height/growth-related pathways as a means for gaining novel mechanistic insights to atrial fibrillation, as well as incorporating height into population screening strategies for atrial fibrillation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases R01-DK101478 and a Linda Pechenik Montague Investigator Award (BFV). SMD was supported by the US Department of Veterans Affairs (IK2-CX001780). This publication does not represent the views of the Department of Veterans Affairs or the United States government. DG was supported by funding from the Wellcome Trust. Genetic sequencing of Penn Medicine Biobank participants was performed in collaboration with Regeneron Genetics Center.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
GWAS summary statistics for height GWAS can be downloaded from the GIANT consortium website (https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files). Summary statistics for atrial fibrillation were contributed by the AFGen consortium (http://afgen.org) and downloaded from the Variant to Function Knowledge Portal (http://www.kp4cd.org/datasets/v2f). The data, analytic methods, and study materials may be made available to other researchers for purposes of reproducing the results or replicating the procedure upon reasonable request to the corresponding author and with the appropriate ethical approval and data sharing agreements.
